Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2021-04-30 | Dr. Ibrahim has significant industry knowledge and drug development experience, as well as broad scientific and medical expertise. |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-04-26